Selected research
Industry Growth & Trends
Global Human Coagulation Factor Ⅷ Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Human Coagulation Factor Ⅷ market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Human Coagulation Factor Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Human Coagulation Factor Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Human Coagulation Factor Ⅷ is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Human Coagulation Factor Ⅷ market include Taibang Bio, Guangdong Shuanglin, Shanghai Laishi, GreenCross, Pfizer, Pfizer, Hualan Bio, Bayer and Baxter, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Human Coagulation Factor Ⅷ market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Human Coagulation Factor Ⅷ market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Human Coagulation Factor Ⅷ market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Human Coagulation Factor Ⅷ.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Human Coagulation Factor Ⅷ market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Human Coagulation Factor Ⅷ Market by Company
Taibang Bio
Guangdong Shuanglin
Shanghai Laishi
GreenCross
Pfizer
Pfizer
Hualan Bio
Bayer
Baxter
Octapharma
Grifols
CSL Behring
Human Coagulation Factor Ⅷ Segment by Type
Recombinant Factor VIII
Human Factor VIII
Human Coagulation Factor Ⅷ Segment by Application
Relvent Bleeding Diseases
Hemophilia A
Human Coagulation Factor Ⅷ Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Coagulation Factor Ⅷ market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Coagulation Factor Ⅷ and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Coagulation Factor Ⅷ.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Human Coagulation Factor Ⅷ companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Factor VIII
- Human Factor VIII
Applications
- Relvent Bleeding Diseases
- Hemophilia A
Companies covered
- Taibang Bio
- Guangdong Shuanglin
- Shanghai Laishi
- GreenCross
- Pfizer
- Pfizer
- Hualan Bio
- Bayer
- Baxter
- Octapharma
- Grifols
- CSL Behring
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Human Coagulation Factor Ⅷ Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Human Coagulation Factor Ⅷ Market Size by Region (2021-2032)
- 1.4.1 Global Human Coagulation Factor Ⅷ Market Size by Region (2021-2026)
- 1.4.2 Global Human Coagulation Factor Ⅷ Market Size by Region (2027-2032)
- 1.5 Key Regions Human Coagulation Factor Ⅷ Market Size (2021-2032)
- 1.5.1 North America Human Coagulation Factor Ⅷ Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Human Coagulation Factor Ⅷ Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Human Coagulation Factor Ⅷ Market Size Growth Rate (2021-2032)
- 1.5.4 South America Human Coagulation Factor Ⅷ Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Human Coagulation Factor Ⅷ Market Size Growth Rate (2021-2032)
2 Human Coagulation Factor Ⅷ Market by Type
- 2.1 Type Introduction
- 2.1.1 Recombinant Factor VIII
- 2.1.2 Human Factor VIII
- 2.2 Global Human Coagulation Factor Ⅷ Market Size by Type
- 2.2.1 Global Human Coagulation Factor Ⅷ Market Size Overview by Type (2021-2032)
- 2.2.2 Global Human Coagulation Factor Ⅷ Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Human Coagulation Factor Ⅷ Market Size Forecasted by Type (2027-2032)
- 2.3 Global Human Coagulation Factor Ⅷ Market Size by Regions
- 2.3.1 North America Human Coagulation Factor Ⅷ Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Human Coagulation Factor Ⅷ Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Human Coagulation Factor Ⅷ Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Human Coagulation Factor Ⅷ Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Human Coagulation Factor Ⅷ Market Size Breakdown by Type (2021-2026)
3 Human Coagulation Factor Ⅷ Market by Application
- 3.1 Type Introduction
- 3.1.1 Relvent Bleeding Diseases
- 3.1.2 Hemophilia A
- 3.2 Global Human Coagulation Factor Ⅷ Market Size by Application
- 3.2.1 Global Human Coagulation Factor Ⅷ Market Size Overview by Application (2021-2032)
- 3.2.2 Global Human Coagulation Factor Ⅷ Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Human Coagulation Factor Ⅷ Market Size Forecasted by Application (2027-2032)
- 3.3 Global Human Coagulation Factor Ⅷ Market Size by Regions
- 3.3.1 North America Human Coagulation Factor Ⅷ Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Human Coagulation Factor Ⅷ Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Human Coagulation Factor Ⅷ Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Human Coagulation Factor Ⅷ Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Human Coagulation Factor Ⅷ Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Human Coagulation Factor Ⅷ Industry Trends
- 4.2 Human Coagulation Factor Ⅷ Industry Drivers
- 4.3 Human Coagulation Factor Ⅷ Industry Opportunities and Challenges
- 4.4 Human Coagulation Factor Ⅷ Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Human Coagulation Factor Ⅷ Revenue (2021-2026)
- 5.2 Global Human Coagulation Factor Ⅷ Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Human Coagulation Factor Ⅷ Key Company Headquarters & Area Served
- 5.4 Global Human Coagulation Factor Ⅷ Company, Product Type & Application
- 5.5 Global Human Coagulation Factor Ⅷ Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Human Coagulation Factor Ⅷ Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Human Coagulation Factor Ⅷ Players Market Share by Revenue in 2025
- 5.6.3 2025 Human Coagulation Factor Ⅷ Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Taibang Bio
- 6.1.1 Taibang Bio Company Information
- 6.1.2 Taibang Bio Business Overview
- 6.1.3 Taibang Bio Human Coagulation Factor Ⅷ Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Taibang Bio Human Coagulation Factor Ⅷ Product Portfolio
- 6.1.5 Taibang Bio Recent Developments
- 6.2 Guangdong Shuanglin
- 6.2.1 Guangdong Shuanglin Company Information
- 6.2.2 Guangdong Shuanglin Business Overview
- 6.2.3 Guangdong Shuanglin Human Coagulation Factor Ⅷ Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Guangdong Shuanglin Human Coagulation Factor Ⅷ Product Portfolio
- 6.2.5 Guangdong Shuanglin Recent Developments
- 6.3 Shanghai Laishi
- 6.3.1 Shanghai Laishi Company Information
- 6.3.2 Shanghai Laishi Business Overview
- 6.3.3 Shanghai Laishi Human Coagulation Factor Ⅷ Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Shanghai Laishi Human Coagulation Factor Ⅷ Product Portfolio
- 6.3.5 Shanghai Laishi Recent Developments
- 6.4 GreenCross
- 6.4.1 GreenCross Company Information
- 6.4.2 GreenCross Business Overview
- 6.4.3 GreenCross Human Coagulation Factor Ⅷ Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 GreenCross Human Coagulation Factor Ⅷ Product Portfolio
- 6.4.5 GreenCross Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Human Coagulation Factor Ⅷ Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Pfizer Human Coagulation Factor Ⅷ Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 Pfizer
- 6.6.1 Pfizer Company Information
- 6.6.2 Pfizer Business Overview
- 6.6.3 Pfizer Human Coagulation Factor Ⅷ Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Pfizer Human Coagulation Factor Ⅷ Product Portfolio
- 6.6.5 Pfizer Recent Developments
- 6.7 Hualan Bio
- 6.7.1 Hualan Bio Company Information
- 6.7.2 Hualan Bio Business Overview
- 6.7.3 Hualan Bio Human Coagulation Factor Ⅷ Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Hualan Bio Human Coagulation Factor Ⅷ Product Portfolio
- 6.7.5 Hualan Bio Recent Developments
- 6.8 Bayer
- 6.8.1 Bayer Company Information
- 6.8.2 Bayer Business Overview
- 6.8.3 Bayer Human Coagulation Factor Ⅷ Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Bayer Human Coagulation Factor Ⅷ Product Portfolio
- 6.8.5 Bayer Recent Developments
- 6.9 Baxter
- 6.9.1 Baxter Company Information
- 6.9.2 Baxter Business Overview
- 6.9.3 Baxter Human Coagulation Factor Ⅷ Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Baxter Human Coagulation Factor Ⅷ Product Portfolio
- 6.9.5 Baxter Recent Developments
- 6.10 Octapharma
- 6.10.1 Octapharma Company Information
- 6.10.2 Octapharma Business Overview
- 6.10.3 Octapharma Human Coagulation Factor Ⅷ Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Octapharma Human Coagulation Factor Ⅷ Product Portfolio
- 6.10.5 Octapharma Recent Developments
- 6.11 Grifols
- 6.11.1 Grifols Company Information
- 6.11.2 Grifols Business Overview
- 6.11.3 Grifols Human Coagulation Factor Ⅷ Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Grifols Human Coagulation Factor Ⅷ Product Portfolio
- 6.11.5 Grifols Recent Developments
- 6.12 CSL Behring
- 6.12.1 CSL Behring Company Information
- 6.12.2 CSL Behring Business Overview
- 6.12.3 CSL Behring Human Coagulation Factor Ⅷ Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 CSL Behring Human Coagulation Factor Ⅷ Product Portfolio
- 6.12.5 CSL Behring Recent Developments
7 North America
- 7.1 North America Human Coagulation Factor Ⅷ Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 7.3 North America Human Coagulation Factor Ⅷ Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Human Coagulation Factor Ⅷ Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 8.3 Europe Human Coagulation Factor Ⅷ Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Human Coagulation Factor Ⅷ Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Human Coagulation Factor Ⅷ Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Human Coagulation Factor Ⅷ Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 10.3 South America Human Coagulation Factor Ⅷ Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Human Coagulation Factor Ⅷ Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Human Coagulation Factor Ⅷ Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Human Coagulation Factor Ⅷ Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst